People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Garuda Therapeutics, Inc. | — | Biotechnology | Series C | $158.0M | $379.8M | 2024 |
| Kyverna Therapeutics, Inc. | — | Biotechnology | Series D+ | $152.0M | $4.0B | 2021 |
| Merge Bio Therapeutics Corp | — | Pharma | Series A | $5.0M | $15.3M | 2025 |
Steve Liapis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steve Liapis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Fred Cohen | 1 | 12 |
| Ryan Jones | 1 | 5 |
| Ian Clark | 1 | 5 |
| Raymond Kelleher | 1 | 4 |
| Eric Aguiar | 1 | 3 |
| Karen Walker | 1 | 2 |
| Shaan I Gandhi | 1 | 2 |
| Brian Kotzin | 1 | 2 |
| James Chung | 1 | 2 |
| Adam Craig | 1 | 2 |
| Peter Maag | 1 | 2 |
| David Kirske | 1 | 2 |
| Rahul I Singhvi | 1 | 1 |
| Laurence I Reid | 1 | 1 |
| Dan Spiegelman | 1 | 1 |
| Beth Spiegelman | 1 | 1 |
| Dominic Borie | 1 | 1 |
| Mark Lipstein | 1 | 1 |
| Clinton Hansen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.